16942-66-8 Usage
General Description
5-METHYL-4-(4-METHYLPHENYL)-1,3-THIAZOL-2-AMINE, also known as MTMT, is a chemical compound with a thiazole ring structure. It is a derivative of thiazole and contains a methyl and 4-methylphenyl group. 5-METHYL-4-(4-METHYLPHENYL)-1,3-THIAZOL-2-AMINE has been studied for its potential pharmacological and biological activities, including its use as an antifungal agent. It may also have applications in the field of medicinal chemistry and drug development. Further research is needed to fully understand the properties and potential uses of 5-METHYL-4-(4-METHYLPHENYL)-1,3-THIAZOL-2-AMINE.
Check Digit Verification of cas no
The CAS Registry Mumber 16942-66-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,6,9,4 and 2 respectively; the second part has 2 digits, 6 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 16942-66:
(7*1)+(6*6)+(5*9)+(4*4)+(3*2)+(2*6)+(1*6)=128
128 % 10 = 8
So 16942-66-8 is a valid CAS Registry Number.
InChI:InChI=1/C11H12N2S/c1-7-3-5-9(6-4-7)10-8(2)14-11(12)13-10/h3-6H,1-2H3,(H2,12,13)
16942-66-8Relevant articles and documents
Promiscuous 2-aminothiazoles (PrATs): A frequent hitting scaffold
Devine, Shane M.,Mulcair, Mark D.,Debono, Cael O.,Leung, Eleanor W. W.,Nissink, J. Willem M.,Lim, San Sui,Chandrashekaran, Indu R.,Vazirani, Mansha,Mohanty, Biswaranjan,Simpson, Jamie S.,Baell, Jonathan B.,Scammells, Peter J.,Norton, Raymond S.,Scanlon, Martin J.
, p. 1205 - 1214 (2015)
We have identified a class of molecules, known as 2-aminothiazoles (2-ATs), as frequent-hitting fragments in biophysical binding assays. This was exemplified by 4-phenylthiazol-2-amine being identified as a hit in 14/14 screens against a diverse range of
IMPROVED MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR
-
Paragraph 00266, (2013/06/27)
Compounds, compositions, and methods for modulation of Hec1/Nek2 interaction are provided. Such compounds disrupt Nek2/Hec1 binding and may be useful as chemotherapeutic agents for neoplastic diseases